KalVista Pharmaceuticals, Inc. (KALV)
- Previous Close
11.65 - Open
11.53 - Bid 11.48 x 400
- Ask 11.56 x 200
- Day's Range
11.28 - 11.75 - 52 Week Range
7.21 - 16.88 - Volume
398,487 - Avg. Volume
824,038 - Market Cap (intraday)
485.165M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-3.12 - Earnings Date Jul 5, 2024 - Jul 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.60
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
www.kalvista.comRecent News: KALV
Performance Overview: KALV
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KALV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KALV
Valuation Measures
Market Cap
485.59M
Enterprise Value
417.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.40
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.50%
Return on Equity (ttm)
-79.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-108.3M
Diluted EPS (ttm)
-3.12
Balance Sheet and Cash Flow
Total Cash (mrq)
75.59M
Total Debt/Equity (mrq)
8.40%
Levered Free Cash Flow (ttm)
-56.13M